MicroFluidic Systems, Inc. is Awarded New Patents in the Area of Automated Biological Agent Identification

FREMONT, Calif., Jan. 4 /PRNewswire/ -- Microfluidic Systems (MFSI), a privately-held company, announced today that it has been awarded a series of patents covering both the components and integrated systems that perform fully automated sample collection through identification of air-borne pathogens such as bacteria, viruses, and toxins. Patent number 7,618,588 covers a low-cost, flow-through, thermal cycling component of the integrated system for amplification of the target organisms via the Polymerase Chain Reaction (PCR) or other similar methods. This is a key step in highly specific organism identification. Patent number 7,633,606 covers the fully integrated system which includes sample collection, agent triggering, sample processing, amplification, and organism identification, as well as toxin protein detection. Within the automated integrated system are key components and methodologies that MFSI has also patented. Several additional patents of different versions of the integrated system have also been allowed.

Microfluidic Systems (MFSI), www.microfluidicsystems.com, was founded in 2001 and is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. MFSI personnel have been involved with the development of automated pathogen detection systems and microfluidics for the US Government and commercial markets for over 25 years, including the world's first miniaturized, portable, battery-operated, real-time, polymerase-chain-reaction (PCR)-based detection system. For more information, please contact Dr. Northrup at MFSI at 510-354-0400 ext 201, or visit the website, www.microfluidicsystems.com.

CONTACT: Dr. M. Allen Northrup of MFSI, +1-510-354-0400, ext 201

Web site: http://www.microfluidicsystems.com/